Erythrocyte sedimentation rate as a marker of inflammation and ongoing coagulation in stroke and transient ischaemic attack

No abstract. South African Medical Journal Vol. 95 (8) 2005: 607-61

A Systematic Review Evaluating the New Media Landscape and its Effects on Skin Cancer Diagnostics, Prognostics, and Prevention

https://openworks.mdanderson.org/sumexp23/1078/thumbnail.jp

Identifying Biomarkers to Select Patients with Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (BRPC, LAPC) for Radiotherapy (RT)

https://openworks.mdanderson.org/sumexp22/1036/thumbnail.jp

The cadaver of a Caucasian man with a supernumerary fourth dorsal interosseous muscle in the right hand: a case report

<p>Abstract</p> <p>Introduction</p> <p>The human hand is a complex anatomic entity consisting of many muscles, nerves, and vessels, thus providing a special ability to perform accurate and meticulous movements. In this group of muscles are the four dorsal interosseous muscles.</p> <p>Case presentation</p> <p>A distinct supernumerary fourth dorsal interosseous muscle was found in the right hand of the cadaver of a 76-year-old Caucasian man without any other concomitant abnormality.</p> <p>Conclusions</p> <p>The presence of such an additional muscle in the hand should be considered in the management of hand deformities, whether the treatment is conservative or surgical.</p

Identifying Differences in Spatial Transcriptomics Between Subtypes of Pancreatic Ductal Adenocarcinoma

https://openworks.mdanderson.org/sumexp22/1072/thumbnail.jp

Effect of health information technology interventions on lipid management in clinical practice: A systematic review of randomized controlled trials

BACKGROUND: Large gaps in lipid treatment and medication adherence persist in high-risk outpatients in the United States. Health information technology (HIT) is being applied to close quality gaps in chronic illness care, but its utility for lipid management has not been widely studied. OBJECTIVE: To perform a qualitative review of the impact of HIT interventions on lipid management processes of care (screening or testing; drug initiation, titration or adherence; or referrals) or clinical outcomes (percent at low density lipoprotein cholesterol goal; absolute lipid levels; absolute risk scores; or cardiac hospitalizations) in outpatients with coronary heart disease or at increased risk. METHODS: PubMed and Google Scholar databases were searched using Medical Subject Headings related to clinical informatics and cholesterol or lipid management. English language articles that described a randomized controlled design, tested at least one HIT tool in high risk outpatients, and reported at least 1 lipid management process measure or clinical outcome, were included. RESULTS: Thirty-four studies that enrolled 87,874 persons were identified. Study ratings, outcomes, and magnitude of effects varied widely. Twenty-three trials reported a significant positive effect from a HIT tool on lipid management, but only 14 showed evidence that HIT interventions improve clinical outcomes. There was mixed evidence that provider-level computerized decision support improves outcomes. There was more evidence in support of patient-level tools that provide connectivity to the healthcare system, as well as system-level interventions that involve database monitoring and outreach by centralized care teams. CONCLUSION: Randomized controlled trials show wide variability in the effects of HIT on lipid management outcomes. Evidence suggests that multilevel HIT approaches that target not only providers but include patients and systems approaches will be needed to improve lipid treatment, adherence and quality

Original Articles National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 -executive summary E M B A R G O E D

Abstract: Various organizations and agencies have issued recommendations for the management of dyslipidemia. Although many commonalities exist among them, material differences are present as well. The leadership of the National Lipid Association (NLA) convened an Expert Panel to develop a consensus set of recommendations for patient-centered management of dyslipidemia in clinical medicine. The current Executive Summary highlights the major conclusions in Part 1 of the recommendations report of the NLA Expert Panel and includes: (1) background and conceptual framework for formulation of the NLA Expert Panel recommendations; (2) screening and classification of lipoprotein lipid levels in adults; (3) targets for intervention in dyslipidemia management; (4) atherosclerotic cardiovascular disease risk assessment and treatment goals based on risk category; (5) atherogenic cholesterol-non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol-as the primary targets of therapy; and (6) lifestyle and drug therapies intended to reduce morbidity and mortality associated with dyslipidemia. Ó 2014 National Lipid Association. All rights reserved. Various organizations and agencies have issued recommendations for the management of dyslipidemia. The current Executive Summary highlights the major conclusions in Part 1 of the recommendations report of the NLA Expert Panel. The Executive Summary does not include a comprehensive reference list, but citations have been included for several key publications. The full report will include additional details on the rationale for the recommendations and citations to published research considered in the panel&apos;s deliberations. A presentation containing the main elements of these recommendations was made available to the public and other organizations involved with the prevention of atherosclerotic cardiovascular disease (ASCVD) to solicit input during an open comment period. Comments and suggestions were received from many members of the NLA as well as other individuals and organizations and were collated for consideration and adjudication by the panel in formulating the final set of recommendations contained herein. Part 1 of the NLA Expert Panel Recommendations for Patient-Centered Management of Dyslipidemia, will cover: Background and conceptual framework for formulation of the NLA Expert Panel recommendations; Screening and classification of lipoprotein lipid levels in adults; Targets for intervention in dyslipidemia management; ASCVD risk assessment and treatment goals based on risk category; Atherogenic cholesterol-non-high-density lipoprotein cholesterol (non-HDL-C) and low-density lipoprotein cholesterol (LDL-C)-as the primary targets of therapy; and Lifestyle and drug therapies intended to reduce morbidity and mortality associated with dyslipidemia

Original Articles National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 -executive summary

Abstract: Various organizations and agencies have issued recommendations for the management of dyslipidemia. Although many commonalities exist among them, material differences are present as well. The leadership of the National Lipid Association (NLA) convened an Expert Panel to develop a consensus set of recommendations for patient-centered management of dyslipidemia in clinical medicine. The current Executive Summary highlights the major conclusions in Part 1 of the recommendations report of the NLA Expert Panel and includes: (1) background and conceptual framework for formulation of the NLA Expert Panel recommendations; (2) screening and classification of lipoprotein lipid levels in adults; (3) targets for intervention in dyslipidemia management; (4) atherosclerotic cardiovascular disease risk assessment and treatment goals based on risk category; (5) atherogenic cholesterol-non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol-as the primary targets of therapy; and (6) lifestyle and drug therapies intended to reduce morbidity and mortality associated with dyslipidemia. Ó 2014 National Lipid Association. All rights reserved. Various organizations and agencies have issued recommendations for the management of dyslipidemia. The current Executive Summary highlights the major conclusions in Part 1 of the recommendations report of the NLA Expert Panel. The Executive Summary does not include a comprehensive reference list, but citations have been included for several key publications. The full report will include additional details on the rationale for the recommendations and citations to published research considered in the panel&apos;s deliberations. A presentation containing the main elements of these recommendations was made available to the public and other organizations involved with the prevention of atherosclerotic cardiovascular disease (ASCVD) to solicit input during an open comment period. Comments and suggestions were received from many members of the NLA as well as other individuals and organizations and were collated for consideration and adjudication by the panel in formulating the final set of recommendations contained herein. Part 1 of the NLA Expert Panel Recommendations for Patient-Centered Management of Dyslipidemia, will cover: Background and conceptual framework for formulation of the NLA Expert Panel recommendations; Screening and classification of lipoprotein lipid levels in adults; Targets for intervention in dyslipidemia management; ASCVD risk assessment and treatment goals based on risk category; Atherogenic cholesterol-non-high-density lipoprotein cholesterol (non-HDL-C) and low-density lipoprotein cholesterol (LDL-C)-as the primary targets of therapy; and Lifestyle and drug therapies intended to reduce morbidity and mortality associated with dyslipidemia

Original Articles National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 -executive summary

Abstract: Various organizations and agencies have issued recommendations for the management of dyslipidemia. Although many commonalities exist among them, material differences are present as well. The leadership of the National Lipid Association (NLA) convened an Expert Panel to develop a consensus set of recommendations for patient-centered management of dyslipidemia in clinical medicine. The current Executive Summary highlights the major conclusions in Part 1 of the recommendations report of the NLA Expert Panel and includes: (1) background and conceptual framework for formulation of the NLA Expert Panel recommendations; (2) screening and classification of lipoprotein lipid levels in adults; (3) targets for intervention in dyslipidemia management; (4) atherosclerotic cardiovascular disease risk assessment and treatment goals based on risk category; (5) atherogenic cholesterol-non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol-as the primary targets of therapy; and (6) lifestyle and drug therapies intended to reduce morbidity and mortality associated with dyslipidemia. Ó 2014 National Lipid Association. All rights reserved. Various organizations and agencies have issued recommendations for the management of dyslipidemia. The current Executive Summary highlights the major conclusions in Part 1 of the recommendations report of the NLA Expert Panel. The Executive Summary does not include a comprehensive reference list, but citations have been included for several key publications. The full report will include additional details on the rationale for the recommendations and citations to published research considered in the panel&apos;s deliberations. A presentation containing the main elements of these recommendations was made available to the public and other organizations involved with the prevention of atherosclerotic cardiovascular disease (ASCVD) to solicit input during an open comment period. Comments and suggestions were received from many members of the NLA as well as other individuals and organizations and were collated for consideration and adjudication by the panel in formulating the final set of recommendations contained herein. Part 1 of the NLA Expert Panel Recommendations for Patient-Centered Management of Dyslipidemia, will cover: Background and conceptual framework for formulation of the NLA Expert Panel recommendations; Screening and classification of lipoprotein lipid levels in adults; Targets for intervention in dyslipidemia management; ASCVD risk assessment and treatment goals based on risk category; Atherogenic cholesterol-non-high-density lipoprotein cholesterol (non-HDL-C) and low-density lipoprotein cholesterol (LDL-C)-as the primary targets of therapy; and Lifestyle and drug therapies intended to reduce morbidity and mortality associated with dyslipidemia

The Pulmonary Venous Ridge Length to Stratify Stroke Risk in Atrial Fibrillation

Purpose of Study: To evaluate the left superior pulmonary venous ridge length (RL) and the left atrial appendage fractal dimension (LAA FD) as predictors of cardioembolic ischemic stroke (CVA) and transient ischemic attack (TIA) in patients with atrial fibrillation (AF). Materials, Methods and Procedures: A multicenter, retrospective multicenter study was conducted on patients with AF who underwent cardiac CT prior to catheter ablation between 01/01/2010 and 12/31/2015. Patients were grouped by the presence or absence of prior CVA/TIA. Patients with mitral stenosis, prior mechanical aortic valve replacement, ascending aortic arch atheroma, highrisk patent foramen ovale, history of atrial septal repair or device, preexisting LAA thrombus or intra-cardiac tumor, or prior open-heart surgery were excluded. Further exclusion was performed for patients with sub-optimal or unavailable cardiac CT imaging by investigators blinded to clinical data. Blinded investigators obtained RL by measuring the distance between the left superior pulmonary venous ostium and the internal ostium of the left atrial appendage. LAA FD was calculated using semi-automated volume rendering and processing software (ImageJ, Bethesda, MD) [1] and LAA FD are presented as means (95% confidence interval) and were compared between groups using unpaired t-tests. Logistic regression analysis was used to construct receiver operating curves and to assess the abilities of RL and LAA FD to predict prior CVA/TIA. Results: 225 patients met inclusion criteria. Mean RL were 4.32 (3.80-4.93) and 5.20 (4.93-5.48) for patients with (n=24; mean age: 59.4; 70.8% male) and without (n=165; mean age: 59.3; 75.4% male) prior CVA/TIA, respectively(p=0.033). Mean LAA FD were 2.29 (95% CI: 2.24-2.34) and 2.33 (2.32-2.34) for patients with (n=22; mean age: 60.3; 68.2% male) and without (n=171; mean age: 59.3; 74.9% male) prior CVA/TIA, respectively (p=0.052). In a regression model including LAA FD, RL, and established predictive markers, only RL predicted prior CVA/TIA (OR 0.73; 0.54 to 0.98; p=0.034). Discussion: Lower RL values were associated with prior CVA/TIA, whereas LAA FD values were similar between patients with AF with and without prior CVA/TIA. RL is a novel marker that may refine clinical decision-making regarding anticoagulation goals and treatment decisions for patients with AF. Future studies with larger samples should investigate the clinical utility of RL to improve CVA/TIA risk stratification of patients with AF and prospectively reduce the incidence of CVA/TIA in this population